A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate whether the IOP (intraocular pressure)
-lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost
and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is
superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time,
once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China
as well as comparison of safety.